gutflix
GI learning, personalised

Summary

EARLY REAL WORLD EXPERIENCE OF FILGOTINIB FOR TREATMENT OF MODERATE-SEVERE ULCERATIVE COLITIS

John Paul Seenan

UEG Week Copenhagen 2023 | Poster

IBD

October 15, 2023

A retrospective review of 28 ulcerative colitis patients treated with filgotinib in Glasgow found that 78.6% reported symptomatic improvement over a median 4-month follow-up, with similar benefit in biologic-naïve and biologic-experienced patients.

KEY POINTS

- Of 28 patients started on filgotinib between July 2022 and February 2023, 78.6% reported symptomatic improvement, including 64.3% of biologic-naïve and 85.7% of biologic-experienced patients.
- Among 17 patients with pre- and post-treatment faecal calprotectin, 70.6% showed improvement with median levels falling from 1567 to 203, though this did not reach statistical significance.
- Side effects occurred in 21.4% and included infections (3 patients), elevated cholesterol or triglycerides (2 patients), and worsening low mood (1 patient).
- Five of 28 patients were considered primary non-responders, with 4 switched to alternative therapies and 1 awaiting surgery; 7 patients required rescue steroids but none required hospital admission.
- The authors conclude that filgotinib appears safe and effective in this cohort, though larger real-world studies are needed to establish its place in routine practice.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/b4a2a56c-743c-11ee-a4c9-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.